

FIGURE 1




FIGURE 2A




FIGURE 2B




FIGURE 3A




FIGURE 3B




FIGURE 4A




FIGURE 4B




FIGURE 5A






FIGURE 5B




FIGURE 6A




FIGURE 6B




FIGURE 7A




FIGURE 7B




FIGURE 8A




FIGURE 8B




FIGURE 9

Weight of Human Colon Adenocarcinoma (HT-29) in CD-1  
Nude Mice Treated with Combination Therapy






FIGURE 10

Weight of Human Colon Adenocarcinoma (HT-29) in CD-1 Nude Mice




FIGURE 11

Growth of Human Colon Adenocarcinoma (HT-29) in CD-1 Nude Mice




FIGURE 12




FIGURE 13






FIGURE 14

Weight of Human Prostate Carcinoma (PC-3)  
in SCID Mice



# FIGURE 15

## Weight of Human Prostate Carcinoma(DU145) in SCID Mice








FIGURE 16



# FIGURE 17

Weight of Human Breast Adenocarcinoma (MDA-MB-231) in CD-1 Nude Mice



Growth of Human Breast Adenocarcinoma (MDA-MB-231) in CD-1 Nude Mice








FIGURE 18



# FIGURE 19

## A Growth of Human Pancreatic Carcinoma (BxPC-3) in CD-1 Nude Mice



## B Weight of Human Pancreatic Carcinoma (BxPC-3) in CD-1 Nude Mice





FIGURE 20

Growth of Human Cervix Epitheloid Carcinoma  
(Hela S3-HU-Resistance) in SCID Mice

A



Weight of Human Cervix Epitheloid Carcinoma  
(Hela S3-HU-Resistance) in SCID Mice

B





FIGURE 21

Weight of Human Cisplatin-Resistant Breast Adenocarcinoma  
Implanted at the Fat Pad of SCID Mice




Statistical Analysis:		P value
Saline : Cisplatin		0.0834
Saline : Taxol		<0.0001
Saline : SEQ ID NO:1		<0.0001
SEQ ID NO:1 : Cisplatin		0.0007
SEQ ID NO:1 : Taxol		0.9547


# FIGURE 22

**Growth Of Human Breast Cancer (MDA-CDDP-S4) In CB-17 SCID Mice Treated With Taxol, SEQ ID NO:1, and Taxol+ SEQ ID NO:1 (Orthotopical transplant)**

**A**



**B**



**C**






FIGURE 23

Weight of Human Taxol-Resistant Breast Adenocarcinoma  
(MDA-MB435-To.1) Implanted at the Fat Pad of SCID Mice

A




B



# FIGURE 24


Growth of Human Breast Adenocarcinoma (MDA-MB435-To. 1)  
in SCID Mice

A



Weight of Human Breast Adenocarcinoma (MDA-MB-435-To. 1)  
in SCID Mice


B



# FIGURE 25

A

## Growth of Promyelocytic Leukemia HL-60 (Taxol-Resistant) in SCID Mice



B

## Weight of Human Promyelocytic Leukemia HL-60 (Taxol-Resistant) in SCID Mice








FIGURE 26

Growth of Human Multi-Drug Resistance Colon Adenocarcinoma (LS513) in SCID Mice

A




B



Weight of Human Colon Multi-Drug Resistance Carcinoma (LS513) in SCID Mice

C



## FIGURE 27

>gi|4557844|ref|NM\_001034.1| Homo sapiens ribonucleotide reductase M2 polypeptide (RRM2), mRNA

```
CCCAGGCGCAGCCAATGGGAAGGGTCGGAGGCATGGCACAGCCAATGGGAAGGGCCGGGGCACC AAAAGCC
AATGGGAAGGGCCGGGAGCGCGCGCGCGGGAGATTAAAGGCTGCTGGAGTGAGGGGTGCCCCGTGCAC
CCTGTCCAGCCGTCCTGTCTGGCTGCTCGCTCTGCTTCGGCTGCGCCCTCCACTATGCTCTCCCTCCGTC
TCCCGCTCGCGCCCATCACGGACCCGACAGCTGACAGCTCTCGCCGCTGAAGGGGCTCAGCTTGGTGCA
CAAGGAGAACAACGCCGCCGGCCCTGAGCGGGACCCGCGTCTGGCCAGCAAGACCCGAGGAGGATCTTC
CAGGAGCCACGGAGCCGAAAACATAAGCAGCTGCCCCCGCGCTGGAGGATGAGCCGCTGCTGAGAGAAA
ACCCCGCGCGCTTTGTCTATCTTCCCATCGAGTACCATGATATCTGGCAGATGTATAAGAAGGCAGAGGC
TTCCTTTTGGACCGCGGAGGAGGTTGACCTCTCCAAGGACATTCAGCACTGGGAATCCCTGAAACCCGAG
GAGAGATATTTTATATCCCATGTTCTGGCTTTCTTTGACGCAAGCGATGGCATAGTAAATGAAAACCTGG
TGGAGCGATTTAGCCAAGAAGTTCAGATTACAGAAGCCCGCTGTTTCTATGGCTTCCAAATTGCCATGGA
AAACATACATTCTGAAATGTATAGTCTTCTTATTGACACTTACATAAAGATCCCAAAGAAAGGGAATTT
CTCTTCAATGCCATTGAAACGATGCTTGTGTCAAGAAGAAGGCAGACTGGGCCCTTGCCTGGATTGGGG
ACAAAGAGGCTACCTATGGTGAAAGTGTGTAGCCCTTTGCTGACGTGGAAGGCATTTCTTTTCCGGTTC
TTTTGCGTCGATATTTCTGGCTCAAGAAACGAGGACTGATGCCCTGGCCTCACATTTTCTAATGAACCTATT
AGCAGAGATGAGGGTTTACACTGTGATTTTGTCTTGCTGATGTTCAAACACCTGGTACACAAACCATCGG
AGGAGAGAGTAAGAGAAATAATTATCAATGCTGTTCCGATAGAACAGGAGTTCCTCACTGAGGCCCTGGC
TGTGAAGCTCATTTGGATGAATTGCACTCTAATGAAGCAATACATTGAGTTTGTGGCAGACAGACTTATG
CTGGAACTGGGTTTTAGCAAGGTTTTACAGAGTAGAGAACCATTGACTTTATGGAGAATATTTCACTGG
AAGGAAAGACTAATCTTTGAGAAGAGAGTAGGCCAGTATCAGAGGATGGGAGTGATGTCAAGTCCAAC
AGAGAAATCTTTTACCTTGGATGCTGACTTCTAAATGAAGTGAAGATGTGCCCTTACTTGGCTGATTTTT
TTTTCCATCTCATAGAAAAATCAGCTGAAGTGTACCAACTAGCCACACCATGAATTGTCCGTAATGT
TCATTAACAGCATCTTTAAAACTGTGTAGCTACCTCACACCAGTCCGTCTGTTTATAGTGTCTGGTAGT
ATCACCTTTTGCCAGAAGGCCCTGGCTGGCTGTGACTTACCATAGCAGTGACAATGGCAGTCTTGGCTTTA
AAGTGAGGGGTGACCTTTAGTGAGCTTAGCACAGCGGGATTAAACAGTCCCTTTAACAGCACAGCCAGT
TAAAAGATGCAGCCTCACTGCTTCAACGAGATTTTAATGTTTACTTAAATATAAACCTGGCACTTTACA
AACAAATAAACATTTGTTTGTACTCACGGCGGCGATAATAGCTTGATTTATTTGGTTTCTACACCAATA
CATTCTCCTGACCACTAATGGGAGCCAAATTCACAAATTCATTAAGTGAATAAGTAAAGTTAACTTGTGTA
GACTAAGCATGTAATTTTAAAGTTTATTTTAATGAATTAAATATTTGTTAACCACTTTAAAGTCAGT
CCTGTGTATACCTAGATATTAGTCAGTTGGTGCCAGATAGAAGACAGGTTGTGTTTTATCCTGTGGCTT
GTGTAGTGTCTGGGATTCTCTGCCCCCTCTGAGTAGAGTGTGTGGGATAAAGGAATCTCTCAGGGCAA
GGAGCTTCTTAAGTTAAATCACTAGAAATTTAGGGGTGATCTGGGCCCTTCATATGTGTGAGAAGCCGTTT
CATTTTATTTCTCACTGTATTTTCTCAACGTCTGGTTGATGAGAAAAAATTCCTGAAGAGTTTTCATAT
GTGGGAGCTAAGGTAGTATTGTAAAATTTCAAGTCATCTTAAACAAAATGATCCAACCTAAGATCTTGCC
CCTGTTAAGTGGTGAAATCAACTAGAGGTGGTTCTACAAGTTGTTCAATTCAGTTTGTGTTGGTGTAAAG
TAGGTTGTGTGAGTTAATTCATTATATTACTATGTCTGTTAAATCAGAAATTTTATTATCTATGTT
CTTCTAGATTTTACCTGTAGTTCATAAAAAAAAAAAAAAAAAAAAAAAAAA
```

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**